UT Dallas spinout Cersci Therapeutics has been acquired in a deal potentially worth nearly $940m, including a $52.5m upfront payment.
Cersci Therapeutics, a US-based neurological medicine spinout of University of Texas at Dallas, was acquired by central nervous system-focused biopharmaceutical firm Acadia Pharmaceuticals for $52.5m yesterday.
The deal mainly consists of Acadia shares. Cersci’s shareholders will also be eligible for up to $887m in milestones and royalties if its assets prove to be commercially viable.
Founded in 2015, Cersci Therapeutics is working on clinical-stage drugs for neurological conditions including strong painkillers for acute and chronic pain disorders that…
